Ibsan 150 mg (Tablet)
Unit Price: ৳ 10.00 (10's pack: ৳ 100.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Irbesartan |
| Company | Acme laboratories ltd |
| Also available as |
Indications
- Treatment of essential hypertension
- Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus
Pharmacology
- Angiotensin II receptor antagonist
- Blocks vasoconstricting effects of angiotensin II
- Blocks aldosterone-secreting effects of angiotensin II
Dosage & Administration
- Usual recommended initial and maintenance dose of Irbesartan 150 mg once daily
- Can be taken with or without food
- Initial therapy for hypertensive type 2 diabetic patients should be Irbesartan 150 mg once daily
- Can be titrated up to Irbesartan 300 mg once daily for treatment of renal disease
- Dosage adjustment not usually necessary for the elderly
- Not recommended for use in children and adolescents
Interaction
- Risk of hypotension when initiating therapy with Irbesartan after prior treatment with high dose diuretics
- Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium not recommended
- Possible increases in serum lithium concentrations and toxicity during concomitant administration of lithium with Irbesartan
- Attenuation of antihypertensive effect when administered simultaneously with non-steroidal anti-inflammatory drugs
Contraindications
- Concomitant use with aliskiren in patients with diabetes and renal impairment (GFR < 60 ml/min)
- Pregnancy
Side Effects
- Diarrhoea
- Fatigue
- Dyspepsia or heartburn
- Dizziness
- Orthostatic hypotension
- Nausea
- Vomiting
- Musculoskeletal pain
- Thrombocytopaenia
- Hyperkalaemia
- Elevated serum creatinine
Pregnancy & Lactation
- Irbesartan is contraindicated in the second and third trimesters of pregnancy
- Precautionary avoidance of use during the first trimester of pregnancy
- Contraindicated during lactation
- Precautions for patients with intravascular volume depletion
Precautions & Warnings
- Precautions for patients with unilateral or bilateral renal artery stenosis, depletion of intravascular volume, aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy, renal impairment, and lactation
- Lower starting dose of Irbesartan for patients undergoing haemodialysis
- No dosage adjustment necessary in patients with mild to moderate hepatic impairment
- Monitoring for hyperkalaemia, caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy, and primary aldosteronism
- Monitoring of serum potassium recommended in patients at risk
Use in Special Populations
- No dosage adjustment necessary in patients with impaired renal function
- Effects of Irbesartan on renal and cardiovascular events not uniform across all subgroups
- Close monitoring of serum potassium recommended for patients at risk of hyperkalaemia
- Special caution indicated in patients with aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy
- Not recommended for patients with primary aldosteronism
Overdose Effects
- No toxicity observed in adults exposed to doses of up to 900 mg/day for 8 weeks
- Manifestations of overdosage expected to be hypotension and tachycardia
Therapeutic Class
- Angiotensin II receptor blocker
Storage Conditions
- Store in a cool and dry place, protected from light